December 11, 2025 15:48

The German plastics processor Renolit has initiated the spin-off of its medical division.
Starting in 2026, Renolit Healthcare will be managed independently through a so-called “virtual carve-out,” while remaining legally part of Renolit SE.

Full legal separation is scheduled by the end of 2027 with the formation of the new company Renolit Healthcare B.V., headquartered in the Netherlands.

According to the company, the spin-off will allow each division to focus on its specific area of expertise: Renolit SE will continue to operate in industrial markets, while Renolit Healthcare will concentrate exclusively on the medical sector, developing polymer solutions for applications such as infusion, transfusion, dialysis systems and biotechnological processes.

“This decision provides clarity and focus,” said Karsten Jänicke, chief executive officer of the German group. “Renolit SE can continue to develop its core industrial markets in a targeted manner, while Renolit Healthcare positions itself as a specialist partner for the healthcare industry. This creates double growth potential.”

The group, headquartered in Worms, operates in more than 20 countries with more than 30 production and sales sites, specializing in films, sheets and other plastic components. In 2024, it recorded annual sales of nearly €1.2 billion with a workforce of 5,000.

© Polimerica -  Reproduction prohibited, all rights reserved